Scholarlink

<p>PIK3CA mutations are common in HR+/HER2− metastatic breast cancer and guide the use of PI3K-targeted therapies. This expert consensus provides recommendations on timing, methods, and interpretation of PIK3CA testing, emphasizing early assessment at metastatic diagnosis, preferred use of NGS panels, and standardized pre-analytical workflows. Reflex and dual-sample strategies can reduce delays and failures. Implementation requires coordinated logistics, education across the diagnostic chain, and equitable access to ensure timely, personalized treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Expert recommendations for PIK3CA testing in HR+/HER2− locally advanced and metastatic breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月15日

查看全文
  • Caterina Marchiò,
  • Federico Rojo,
  • Ellen R. Copson,
  • Fernando Schmitt,
  • Beatriz Bellosillo,
  • Carlo Fremd

摘要

PIK3CA mutations are common in HR+/HER2− metastatic breast cancer and guide the use of PI3K-targeted therapies. This expert consensus provides recommendations on timing, methods, and interpretation of PIK3CA testing, emphasizing early assessment at metastatic diagnosis, preferred use of NGS panels, and standardized pre-analytical workflows. Reflex and dual-sample strategies can reduce delays and failures. Implementation requires coordinated logistics, education across the diagnostic chain, and equitable access to ensure timely, personalized treatment.